• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Doxorubicin
    3 Drugs classified under this active ingredient

    All the Active Ingredient Drugs

    partial basket chart

    Anthracycline. Doxorubicin (HCl) 2 mg/ml.
    I.V. INFUS. (liposome inject.): 1. Ovarian
    cancer: 50 mg/m2 I.V at initial rate of 1
    mg/min. Incr. rate if no infus. related
    AE’s observed over 1 hr., every 4 wks.
    for as long as pt. does not progress,
    shows no signs cardiotox. and cont. tol.
    to tmt. 4 courses recommend. See lit.
    AIDS KS: 20 mg/m2 I.V. over 30 mins.
    once every 3 wks as long as pt.
    tolerates and responds.
    Monother. in metastat. breast cancer,
    where there is incr. cardiac risk. 1st or 2nd
    line ther. of AIDS-related Kaposis sarcoma in pts. with low cd 4 counts and extens. mucocutan. or visc. dis. Tmt. of pts with metastat. carcinoma of the ovary who are refract. to both paclitaxel and platinumbased chemother. regimens and who may also be refract. to topotecan. Refract. is defined as a pt. having progress. dis. while on tmt., or within 6 mths of completing tmt.

    Doxorubicin Teva
    partial basket chart
    Doxorubicin Teva

    Anthracycline. Doxorubicin HCl 2 mg/ml.
    VIALS (sol. for inject.): 25 ml, 100 ml.
    Recommend. total dose: 550 mg/m² I.V.
    See lit. Recommend. schedule: 60-75
    mg/m² as single I.V. at 21-day intervals.
    See lit.
    To produce regress. in dissem. neoplastic
    conds. e.g. acute lymphoblast. leuk., acute
    myeloblast. leuk., Wilms’ tumor, nblast.,
    soft tissue/bone sarc., carc. breast, ovary,
    transient cell bladder carc., thyroid carc.,
    lymph of both Hodgkin’s and non-
    Hodgkin’s bronchogen. carc., gastr. carc.

    Lipodox Liposomal
    Taro International Ltd
    not in the basket chart
    Lipodox Liposomal

    Doxorubicin 2mg/ml.
    VIAL. (Liposome Concentrate for Sol. for IV infus.: 10, 25ml
    Dosage must be ajust. individ. according to the pt. indication and tolerability.
    1st or 2nd  line ther. of AIDS related Kaposis sarcoma in pts. with low CD 4 counts and extensive mucocutaneous or visceral dis.
    Tmt. of pts. with metastat. carcinoma of the ovary who are refract.to both paclitaxel and platinium-based chemother. regimens and who may also be refract. to topotecan. Refract. is defined as a pt. having progress. dis.while on tmt. or within 6 mnths. of complet. tmt.
    As monother.for pts. with metastat. breast cancer where there is an incr.card. risk.
    In comb. with bortezomib for the tmt. of progress. multiplemyeloma in pts. who have received at least one prior ther. and who have already undergone or are unsuit. for bone marrow transplant.
    C/I: Hypersens.
    Hypersens. peanut or soya.
    Pts. with AIDS-KS that may be effectively treated with local therapy or systemic alfa-interferon.